TP53 rs1042522: Understanding the Pro72Arg Variant
The rs1042522 variant, commonly known as Pro72Arg, is a frequent genetic change located within the TP53 gene. It is widely studied for its potential associations with various cancer risks and is subject to ongoing clinical evaluation to determine its precise impact on human health.
What each genotype means
Proline homozygous genotype
This genotype results in the Proline (Pro) version of the TP53 protein at position 72. Some research suggests individuals with this genotype may show different responses to certain chemotherapy regimens compared to those with the G allele, and some studies have observed potential longevity benefits in specific populations. Please discuss any concerns regarding medication response or cancer risk with your healthcare provider.
This genotype is common globally, though its frequency varies significantly across different ancestral populations.
Heterozygous genotype
This genotype indicates you carry one copy of the Proline-encoding allele and one copy of the Arginine-encoding allele. Research has explored associations between this heterozygous state and varying susceptibility to certain cancers, though results are often mixed and depend on the specific population studied. If you are undergoing cancer treatment, consult your oncologist regarding how this variant might influence your specific therapy plan.
This is a very common genotype found in most human populations worldwide.
Arginine homozygous genotype
This genotype results in the Arginine (Arg) version of the TP53 protein at position 72. Some clinical studies have associated this genotype with altered responses to specific chemotherapy drugs, such as decreased sensitivity to certain platinum-based treatments in specific cancer types. Always discuss the implications of your genetic profile with your clinician or pharmacist when considering treatment options.
This is a common genotype, frequently observed across diverse global populations.
What is rs1042522?
The rs1042522 variant is a single nucleotide polymorphism (SNP) located in the TP53 gene. In genetic terms, this specific change results in an amino acid substitution where proline is replaced by arginine at position 72 of the p53 protein. Because this change occurs within the coding region of the gene, it is often referred to as the Pro72Arg variant. Scientists track this specific location in the human genome to understand how such variations might influence protein function. While many variants in the genome are neutral, researchers focus on rs1042522 because the TP53 gene plays a critical role in cellular health, making even small changes in its structure a subject of significant scientific interest.
The Role of the TP53 Gene
The TP53 gene is often described as the 'guardian of the genome' because it provides instructions for making a protein called p53. This protein acts as a tumor suppressor, meaning it helps regulate cell division and prevents cells from growing or dividing too rapidly or in an uncontrolled way. When DNA damage occurs, the p53 protein helps determine whether the cell should repair the damage or undergo a process called apoptosis, which is programmed cell death. By ensuring that cells with damaged DNA do not replicate, the p53 protein plays a vital role in maintaining genomic stability. Because of its essential function, researchers closely monitor variants within this gene to see if they alter the protein's ability to protect the body from abnormal cell growth.
Research and Clinical Associations
Research into rs1042522 has explored its potential links to various health conditions, including different types of cancer. Some studies have investigated whether this variant influences the risk of colorectal cancer or malignant bone tumors, though findings across different populations can be mixed. It is important to note that the ClinGen TP53 Variant Curation Expert Panel works to refine clinical interpretation guidelines for TP53 variants to improve the accuracy of risk assessments, particularly for conditions like Li-Fraumeni syndrome. Because the evidence regarding the specific impact of rs1042522 is complex and often context-dependent, it is not used as a standalone diagnostic tool. Current research emphasizes that genetic risk is rarely determined by a single variant alone, and environmental or other genetic factors often play significant roles in health outcomes.
Understanding Your Information
If you have received information about your status for rs1042522, it is essential to understand that this is a common variant found in many healthy individuals. Having a specific genotype for this SNP does not constitute a medical diagnosis or a definitive prediction of future health. Genetic information is complex, and clinical interpretation requires a professional who can look at your entire health history and family background. You cannot use this information to make personal medical decisions, such as starting or stopping treatments. If you have concerns about your genetic health or cancer risk, the most appropriate step is to consult with a qualified healthcare provider or a genetic counselor. They can help you interpret your results within the context of your overall health and provide guidance based on established clinical standards.
How common is this variant?
The rs1042522 variant is common in most global populations, with the proline and arginine alleles appearing at varying frequencies across different ancestral groups.
Frequently asked questions
Is rs1042522 a cause of cancer?
No, rs1042522 is a common genetic variant and is not considered a direct cause of cancer. While researchers study its potential influence on cancer risk, it is not a pathogenic mutation that guarantees the development of disease.
Should I be worried if I have the GG genotype?
There is no reason for concern based on this genotype alone. It is a common variation found in many healthy people, and genetic variants are only one small part of your overall health profile.
How can I get tested for this variant?
Testing for specific SNPs is often included in commercial genetic health reports. However, you should discuss the clinical relevance of such testing with a doctor or genetic counselor before pursuing it.
Does this variant affect how I respond to medication?
There is no standard clinical evidence suggesting that rs1042522 dictates specific medication responses. Always consult your pharmacist or physician regarding any questions about your prescribed medications.
Sources & further reading
Educational information only, last refreshed 9/24/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1042522?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TP53
Pathogenic missense variant (p.Arg248Gln) associated with Li-Fraumeni syndrome.
Functional codon 72 polymorphism (Arg72Pro) affecting apoptotic capability and associated with differential susceptibility to multiple cancer types.
Functional 3' UTR polyadenylation signal polymorphism altering TP53 transcription termination, showing population-specific baseline carrier frequencies across global groups.
Pathogenic hotspot variant (p.Arg273His) in TP53 predisposing carriers to early-onset sarcomas, breast cancers, and leukemias.
Li-Fraumeni syndrome missense variant (p.Arg248Trp) causing loss of tumor suppressor function and multi-cancer predisposition.
Synonymous and regulatory variant in linkage with TP53 codon 72 that modulates blastocyst implantation competence and the risk of recurrent implantation failure.